|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6950 MYR | -.--% |
|
-.--% | +0.72% |
| Market Cap | 154M 37.65M 32.72M 30.55M 28.04M 52.88M 3.59B 53.8M 360M 141M 1.79B 141M 138M 5.9B | P/E 2026 * |
9.87x | P/E 2027 * | 9.34x |
|---|---|---|---|---|---|
| Enterprise Value | 154M 37.65M 32.72M 30.55M 28.04M 52.88M 3.59B 53.8M 360M 141M 1.79B 141M 138M 5.9B | EV / Sales 2026 * |
0.63x | EV / Sales 2027 * | 0.58x |
| Free-Float |
15.82% | Yield 2026 * |
3.6% | Yield 2027 * | 3.88% |
| 1 month | +0.72% | ||
| 3 months | +1.46% | ||
| 6 months | +1.46% | ||
| Current year | +0.72% |
| 1 month | 0.68 | 0.7 | |
| Current year | 0.62 | 0.72 | |
| 1 year | 0.62 | 0.72 | |
| 3 years | 0.58 | 0.8 | |
| 5 years | 0.58 | 0.8 | |
| 10 years | 0.57 | 1.34 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ban Keong Lim
CEO | Chief Executive Officer | 55 | 2015-03-31 |
Yan San Chan
DFI | Director of Finance/CFO | 56 | 2013-12-31 |
| Chief Operating Officer | 38 | 2021-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 77 | 2015-03-31 | |
Ban Keong Lim
BRD | Director/Board Member | 55 | 2015-03-31 |
Kam Weng Foong
BRD | Director/Board Member | 66 | 2015-03-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 1/31/25 | Buy | Chief Executive Officer | 110,000 | 0.0497% | ||
| 9/22/23 | Buy | Chief Executive Officer | 17,000 | 0.0077% | ||
| 9/8/23 | Buy | Chief Executive Officer | 103,000 | 0.0466% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | +10.32% | -0.71% | 37.74M | ||
| -2.39% | -6.36% | +47.10% | +149.66% | 1,024B | ||
| -0.76% | -4.34% | +52.04% | +49.09% | 618B | ||
| -2.33% | -4.60% | +25.55% | +64.44% | 443B | ||
| +0.68% | -1.14% | +38.47% | +33.36% | 349B | ||
| -1.66% | -3.13% | +32.18% | +39.79% | 297B | ||
| -8.96% | -10.77% | +3.57% | +5.50% | 264B | ||
| -1.37% | -7.41% | -2.10% | -43.67% | 209B | ||
| -1.63% | +0.69% | +27.62% | +64.23% | 208B | ||
| +0.72% | +0.48% | +15.88% | +73.64% | 162B | ||
| Average | -1.38% | -2.83% | +25.06% | +43.53% | 357.38B | |
| Weighted average by Cap. | -0.98% | -3.91% | +34.56% | +70.87% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 244M 59.48M 51.69M 48.26M 44.3M 83.54M 5.67B 84.99M 569M 223M 2.83B 223M 218M 9.32B | 265M 64.78M 56.3M 52.56M 48.25M 90.98M 6.17B 92.56M 620M 243M 3.08B 243M 238M 10.16B |
| Net income | 15.6M 3.81M 3.31M 3.09M 2.84M 5.35M 363M 5.44M 36.44M 14.27M 181M 14.31M 13.99M 597M | 15.6M 3.81M 3.31M 3.09M 2.84M 5.35M 363M 5.44M 36.44M 14.27M 181M 14.31M 13.99M 597M |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-28 | MYR 0.6950 | -.--% | 3,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RHONEMA Stock
Select your edition
All financial news and data tailored to specific country editions
















